Arbutus to Participate in Virtual Fireside Chat at H.C. Wainwright Hepatitis B Virus (HBV) Mini-Conference
October 13, 2020 08:00 ET
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., Oct. 13, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with...
Arbutus Announces AB-729 90 mg Single-Dose Week 12 Data in Chronic Hepatitis B Subjects Demonstrating Significant and Continuous Reductions in HBsAg
September 15, 2020 07:30 ET
|
Arbutus Biopharma Corporation
Mean HBsAg reduction of 1.23 log10 IU/mL at week 12 with a favorable safety and tolerability profile WARMINSTER, Pa., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:...
Vir Biotechnology Presents Data on VIR-2218 from Clinical Studies for the Treatment of Hepatitis B at the EASL Digital International Liver Congress™
August 20, 2020 08:00 ET
|
Vir Biotechnology, Inc.
SAN FRANCISCO, Aug. 20, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today...
Distinguished Scientific Leaders to Join Enochian BioSciences Hepatitis B Scientific Advisory Board
July 27, 2020 08:00 ET
|
Enochian Biosciences, Inc.
Drs. Carol Brosgart, Peter Revill and Fabien Zoulim will advise on development of a cure for Hepatitis B LOS ANGELES, July 27, 2020 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) − Enochian BioSciences, a...
Vir Biotechnology Initiates Phase 1 Clinical Trial of VIR-3434 for Chronic Hepatitis B Virus Infection
May 27, 2020 08:00 ET
|
Vir Biotechnology, Inc.
SAN FRANCISCO, May 27, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the initiation of a Phase 1 clinical trial of VIR-3434, an investigational monoclonal antibody...
Enochian Biosciences Announces Three Scientific Presentations on Potential HIV and HBV Cures
May 13, 2020 08:00 ET
|
Enochian Biosciences, Inc.
• First presentation of a novel approach to potentially cure HIV - An in vivo study demonstrated a 164 percent increase in engraftment of genetically modified cells Poster Presentation -...
VIR-2218 Demonstrates Dose-Dependent and Durable Reductions of Hepatitis B Surface Antigen in Phase 1/2 Trial
April 15, 2020 16:01 ET
|
Vir Biotechnology, Inc.
SAN FRANCISCO, April 15, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (NASDAQ: VIR) today announced additional interim data from the ongoing Phase 2 trial in patients and results from the Phase...
Enochian Biosciences Announces Scientific Presentation of a Novel Approach to Potentially Cure Hepatitis B Virus
December 10, 2019 07:00 ET
|
Enochian Biosciences, Inc.
A new gene therapy kills up to 98 percent of HBV infected cells but not uninfected cells. Results from a commonly used mouse model to study HBV confirmed the HBV-infected cell-specific killing effect...
Enochian Biosciences Expands its Infectious Disease Pipeline by Entering into an Agreement in Principle to Acquire an Exclusive License for a Novel Hepatitis B Virus Treatment
November 25, 2019 07:00 ET
|
Enochian Biosciences, Inc.
Agreement provides Enochian with exclusive rights to develop and commercialize a HBV treatment with a novel mechanism of actionAbstract accepted highlighting the in vivo and in vitro data from...
Assembly Biosciences to Present at the Jefferies London Healthcare Conference
November 08, 2017 07:00 ET
|
Assembly Biosciences, Inc.
INDIANAPOLIS, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of...